Abstract 1845P
Background
ICIs are used in many solid tumors and is better tolerated than chemotherapy. However, irAEs are a concerning toxicity. Studies suggest that BMI may influence irAEs rates. We conducted a population-level study to evaluate BMI on irAEs and acute care use in patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of solid tumors patients initiating ICI therapy in Ontario, Canada from June 2012-October 2018. We collected information on socio-demographics including BMI at start of ICI, clinical covariates and outcomes including acute care use and irAEs within 120 days of the last ICI dose. Multivariable Fine Gray competing risk analyses evaluated the impact of BMI on irAEs and acute care use, treating death as a competing event.
Results
Among 4683 patients, median age was 67, 57% were male; 46% had lung cancer, 35% melanoma, 9% renal; Median BMI was 26.1 (3% low, 29% normal, 27% overweight, 19% obese). Overall, 57% had an acute care episode while 7% of patients had an irAE requiring hospitalization. Increased BMI was associated with increased rate of irAEs (aHR=1.03 per 1 unit increase, 95% CI [1.01-1.04] p<0.001). Compared to patients with normal BMI, obese (aHR=1.60 [1.21-2.11] p<0.001) patients had a higher rate of irAEs. Subgroup analysis by gender found that females with increasing BMI (aHR=1.03 per unit increase [1.00-1.06] p=0.02) and obesity (aHR=2.01 [1.30-3.09] p=0.002) had higher rates of irAEs. Disease site analyses found that in patients with melanoma, obesity when compared to normal BMI (aHR=1.67 [1.10-2.53] p=0.02) was associated with increase in irAEs. In particular, in females with melanoma, obesity compared to normal BMI was strongly associated with increased irAEs (aHR=2.60 [1.36-4.96] p<0.004). BMI was not associated with overall general acute care use as a continuous or categorical variable (p>0.05).
Conclusions
Increasing BMI and obesity is associated with increasing risk for irAEs but not acute care use. The association was strongest for female patients and those with melanoma. Further research is needed to understand the mechanism of action behind this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Eng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1864P - Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
Presenter: Didier Debieuvre
Session: Poster session 12
1865P - DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancers
Presenter: Alexey Tryakin
Session: Poster session 12
1866P - Metabolic and quality of life changes with the use of dexamethasone pre-paclitaxel in patients with breast cancer
Presenter: VANESSA SCONTRE
Session: Poster session 12
1867P - Efficacy of lower dose of dexamethasone premedication in patient receiving docetaxel-based chemotherapy in preventing hypersensitivity reaction: A randomized controlled trial
Presenter: Sitthichai Chanmaniloet
Session: Poster session 12
1868P - Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction: Pac-HSR score
Presenter: Radasar Sukphinetkul
Session: Poster session 12
1869P - Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
Presenter: Anton Snegovoy
Session: Poster session 12
1870P - Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy
Presenter: Giovanna Giannecchini
Session: Poster session 12
1871P - Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection
Presenter: Athina Kostara
Session: Poster session 12
1872P - Evaluation of PROMISE, grim, and cti scores for predicting 90-day mortality in hospitalized cancer patients: A retrospective analysis at a single center
Presenter: Galip Can Uyar
Session: Poster session 12
1873P - Thalidomide for the treatment of chemotherapy-induced night sweats in patients with pancreatic cancer
Presenter: Nan Lu
Session: Poster session 12